Call for Abstract

10th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, will be organized around the theme “De novo in Drug Delivery Systems”

Pharmaceutica 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Pharmaceutica 2017

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Pharmaceutics is the study of relationships between preformulationpharmaceutical formulation, delivery, disposition and clinical response. The inherent instability nature of a new drug will alter its desired form into undesired form when presented in a suitable dosage form with the excipient/s upon storage. In early days this process was confined only for assessing few characteristics, but today this process is being considered as a formulation strategy and hence tremendous technological advancement has been achieved in this field which enables us to save time and money through planned management system and hence impacts Pharmaceutica 2017 to be a formulation conference. Use of glorious statistical software even based on artificial neural networking are made the task of preformulation and optimization process easier. Role of preformulation studies techniques like freeze drying aspects projects the event Pharmaceutica 2017 to pose as a freeze drying meeting in drug discoverydrug development plays major role in pharmaceutical formulation development and the studies will help in different dosage forms design. With the increasing number of novel and specialized compounds being developed, a "one size fits all" approach to drug formulation and delivery is no longer optimal, necessitating the consideration of formulations unique to each drug. NDDS conference will discuss on Early Approaches, Present Scenario and Future Prospects of Preformulation events. There are more than 1400 sustained or controlled release drugs have been approved all over the world. Pharmaceutical conferences discuss the state-of-art technology being applied and involve advances in formulation studies. 

Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall international pharmaceutical market. The utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.

 

  • Track 1-1Preformulation in Drug Discovery
  • Track 1-2Preformulation in Drug Development
  • Track 1-3Drug Formulation Considerations
  • Track 1-4Major Challenges in Drug Development
  • Track 1-5Physiological Drug Environment
  • Track 1-6Freeze Drying
  • Track 1-7Hot Melt Extrusion

Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.

Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of action is determined by that drug’s binding with a receptor. Receptors may be present on neurons in the central nervous system (i.e., opiate receptors) to depress pain sensation, on cardiac muscle to affect the intensity of contraction, or even within bacteria to disrupt maintenance of the bacterial cell wall.

 

  • Track 2-1Pharmacokinetic Parameters
  • Track 2-2Pharmacodynamic Parameters
  • Track 2-3Absorption of Drugs
  • Track 2-4Distribution of Drugs
  • Track 2-5Biotransformation/Metabolism
  • Track 2-6Excretion of Drugs
  • Track 2-7Pharmacodynamics

The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to predict the conformation of the small molecule and to model conformational changes in the biological target that may occur when the small molecule binds to it. The therapeutic response of a drug depends upon the interaction of drug molecules with cell on cell membrane related biological events at receptor sites in concentration dependent manner.

Selective and effective localization of the pharmacologically-active moiety at preidentified target(s) in therapeutic concentration, while restricting its access to non-target(s) normal cellular linings, thus minimizing toxic effects and maximizing the therapeutic index accounts from effective and efficient drug delivery.

Molecular mechanics methods may also be used to provide semi-quantitative prediction of the binding affinity. Also, knowledge-based scoring function may be used to provide binding affinity estimates. These methods use linear regression, machine learning, neural nets or other statistical techniques to derive predictive binding affinity equations by fitting experimental affinities to computationally derived interaction energies between the small molecule and the target.

  • Track 3-1Drug Targeting strategies
  • Track 3-2Factors influencing Drug Targeting
  • Track 3-3Advances in Drug Targeting components
  • Track 3-4Recent Approaches to Drug Targeting
  • Track 3-5Rational Drug Design
  • Track 3-6Computer Aided Drug Design

A route of administration is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be classified based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).

Routes of administration are usually classified by application location (or exposition). The route or course the active substance takes from application location to the location where it has its target effect is usually rather a matter of pharmacokinetics (concerning the processes of uptake, distribution, and elimination of drugs). Nevertheless, some routes, especially the transdermal or transmucosal routes are commonly referred to routes of administration. The location of the target effect of active substances is usually rather a matter of pharmacodynamics (concerning e.g. the physiological effects of drugs). Furthermore, there is also a classification of routes of administration that basically distinguishes whether the effect is local (in "topical" administration) or systemic (in "enteral" or "parenteral" administration).

 

  • Track 4-1Oral Drug Delivery
  • Track 4-2Mucosal Drug Delivery
  • Track 4-3Buccal Drug Delivery
  • Track 4-4Nasal Drug Delivery
  • Track 4-5Ophthalmic Drug Delivery
  • Track 4-6Topical Drug Delivery
  • Track 4-7Parenteral Drug Delivery
  • Track 4-8Rectal Drug Delivery
  • Track 4-9Vaginal Drug Delivery
  • Track 4-10Geriatric Drug Delivery
  • Track 4-11Paediatric Drug Delivery

Nanoparticles (NPs) occur naturally and have been in existence for thousands of years as products of combustion and cooking of food. Nanomaterials differ significantly from other materials due to the following two major principal factors: the increased surface area and quantum effects. These factors can enhance properties such as reactivity, strength, electrical characteristics, and in vivo behaviour. As the particle size decreases, a greater proportion of atoms are found at the surface compared to inside. An NP has a much greater surface area per unit mass compared with larger particles, leading to greater reactivity. In tandem with surface area effects, quantum effects can begin to dominate the properties of matter as size is reduced to the nanoscale. These can affect the optical, electrical, and magnetic behaviour of materials. Their in vivo behaviour can be from increased absorption to high toxicity of nanomaterials.

 
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, Peptisyntha Inc. and Lonza Inc.   
 
The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
 
  • Track 5-1Liposomal Drug Delivery Systems
  • Track 5-2Microemulsions and Nanoemulsions
  • Track 5-3Solid Lipid Nano and Microparticles
  • Track 5-4Polymers
  • Track 5-5Organic Nanotubes: Promising Vehicles for Drug Delivery
  • Track 5-6Dendrimers
  • Track 5-7Micelles
  • Track 5-8Cyclodextrins
  • Track 5-9Nanogels
  • Track 5-10Metal Nanoparticles and Quantum Dots
Nanotechnology has finally and firmly entered the realm of drug delivery. Performances of intelligent drug delivery systems are continuously improved with the purpose to maximize therapeutic activity and to minimize undesirable side-effects. There are multiple Applications of Nanotechnology in Drug Delivery systems are based on micelles, polymeric nanoparticles, and dendrimers. Polymeric carbon nanotubes and many others demonstrate a broad variety of useful properties. The following dosage forms using Nanotechnology in Drug Delivery Systems are Liposomes as potential drug carrier systems for drug delivery and project Pharmaceutica 2016 to pose as a liposome event during the conference , Techniques for the preparation of solid lipid nano and microparticles, Nanoemulsions applications, Nanoparticle based Drug Delivery Systems for Treatment of Infectious Diseases, Dermal, Transdermal Drug Delivery, Insulin Drug Delivery and Organic Nanotubes as a Promising Vehicles for Drug Delivery. NDDS conference will discuss on the Current Status and Future Scope for Nanomaterials in Drug Delivery and reflect on pharmaceutical technology conference. Interestingly pharmaceutical sciences are also using nanoparticles to reduce toxicity and side effects of drugs. The potential to cross the Blood Brain Barrier (BBB) has open new ways for drug delivery into the brain. In addition, the nanosize also allows for access into the cell and various cellular compartments including the nucleus. Nanoparticles are also considered to have the potential as novel intravascular or cellular probes for both diagnostic and therapeutic purposes (drug/gene delivery), which is expected to generate innovations and play a critical role in medicine.
 
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, Peptisyntha Inc. and Lonza Inc.   
 
The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.

 

  • Track 6-1Controlled Drug Delivery
  • Track 6-2Transdermal Drug Delivery
  • Track 6-3Dermal Drug Delivery
  • Track 6-4Antimicrobial nanoemulsions
  • Track 6-5Cancer therapy
  • Track 6-6Treatment of other diseases
  • Track 6-7Oral delivery of poorly soluble drugs

Size reduction is a fundamental unit operation having important applications in pharmacy. It helps in improving solubility and bioavailability, reducing toxicity, enhancing release and providing better formulation opportunities for drugs. In most of the cases, size reduction is limited to micron size range, for example, various pharmaceutical dosage forms like powder, emulsion, suspension etc. Drugs in the nanometer size range enhance performance in a variety of dosage forms. Major advantages of nanosizing include (i) increased surface area, (ii) enhanced solubility, (iii) increased rate of dissolution, (iv) increased oral bioavailability, (v) more rapid onset of therapeutic action, (vi) less amount of dose required, (vii) decreased fed/fasted variability, and (viii) decreased patient-to-patient variability.

Pharmaceutical nanotechnology has provided more fine-tuned diagnosis and focused treatment of disease at a molecular level. Pharmaceutical nanotechnology is most innovative and highly specialized field, which will revolutionize the pharmaceutical industry in near future. Pharmaceutical nanotechnology presents revolutionary opportunities to fight against many diseases. It helps in detecting the antigen associated with diseases such as cancer, diabetes mellitus, neurodegenerative diseases, as well as detecting the microorganisms and viruses associated with infections. It is expected that in next 10 years market will be flooded with nanotechnology devised medicine.

 

  • Track 7-1Pharmaceutical Nanotechnology based Systems
  • Track 7-2Characterization of Pharmaceutical Nanotools
  • Track 7-3Engineering of Pharmaceutical Nanosystems
  • Track 7-4Applications of Pharmaceutical Nanotools
  • Track 7-5Challenges to Pharmaceutical Nanotechnology
  • Track 7-6Future Prospects of Pharmaceutical Nanotechnology

Smart drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages.

Targeted drug delivery systems have been developed to optimize regenerative techniques. The system is based on a method that delivers a certain amount of a therapeutic agent for a prolonged period of time to a targeted diseased area within the body. This helps maintain the required plasma and tissue drug levels in the body, thereby preventing any damage to the healthy tissue via the drug. The drug delivery system is highly integrated and requires various disciplines, such as chemists, biologists, and engineers, to join forces to optimize this system.

 

  • Track 8-1Targeted Drug Delivery
  • Track 8-2Proteins and Surfaces
  • Track 8-3Mucosal Drug Delivery
  • Track 8-4Skin Drug Delivery
  • Track 8-5Pulmonary Drug Delivery
  • Track 8-6Cancer Delivery
  • Track 8-7Insulin Delivery
  • Track 8-8Self-Emulsifying Drug Delivery Systems (SEDDS)
  • Track 8-92D and 3D Printing In Drug Delivery
  • Track 8-10BioMEMS
  • Track 8-11Blood Brain Barrier Delivery
  • Track 8-12Antibody Targeted-Drug Conjugates
  • Track 8-13Nucleic Acid Drug Delivery Systems
  • Track 8-14Gene Delivery

A biomaterial is any substance that has been engineered to interact with biological systems for a medical purpose - either a therapeutic (treat, augment, repair or replace a tissue function of the body) or a diagnostic one. Biomaterials can be derived either from nature or synthesized in the laboratory using a variety of chemical approaches utilizing metallic components, polymers, ceramics or composite materials. They are often used and/or adapted for a medical application, and thus comprise whole or part of a living structure or biomedical device which performs, augments, or replaces a natural function. Such functions may be benign, like being used for a heart valve, or may be bioactive with a more interactive functionality such as hydroxy-apatite coated hip implants. Biomaterials are also used every day in dental applications, surgery, and drug delivery. For example, a construct with impregnated pharmaceutical products can be placed into the body, which permits the prolonged release of a drug over an extended period of time. A biomaterial may also be an autograft, allograft or xenograft used as a transplant material.

 

  • Track 9-1Cells and Proteins
  • Track 9-2Proteins and Surfaces
  • Track 9-3Ceramics and Metals
  • Track 9-4Polymers
  • Track 9-5Wound Healing
  • Track 9-6Translational Sciences
  • Track 9-7Biomaterials Processing & Devices
  • Track 9-83D Printing Technologies
  • Track 9-9Biomaterials & Therapeutics
  • Track 9-10Musculoskeletal
  • Track 9-11Nanomaterials & Nanotechnologies
  • Track 9-12Tissue Regeneration

Vaccine is a material that induces an immunologically mediated resistance to a disease but not necessarily an infection. Vaccines are generally composed of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Sub-unit vaccines though exceptionally selective and specific in reacting with antibodies often fail to show such reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. Delivery of antigens from oil-based adjuvants such as Freunds adjuvant lead to a reduction in the number of doses of vaccine to be administered but due to toxicity concerns like inductions of granulomas at the injection site, such adjuvants are not widely used. FDA approved adjuvants for human uses are aluminium hydroxide and aluminium phosphate in the form of alum. Hence, search for safer and potent adjuvants resulted in the formulation of antigen into delivery systems that administer antigen in particulate form rather than solution form.

Other reasons driving the development of vaccines as controlled drug delivery systems are as follows:

  • Immunization failure with conventional immunization regimen involving prime doses and booster doses, as patients neglect the latter. Vaccines delivery systems on the other hand:
  • Allow for the incorporation of doses of antigens so that booster doses are no longer necessary as antigens are released slowly in a controlled manner.
  • Control the spatial and temporal presentation of antigens to the immune system there by promoting their targeting straight to the immune cells.

 

  • Track 10-1Cancer vaccines
  • Track 10-2Influenza vaccines/virus
  • Track 10-3Novel vaccines
  • Track 10-4Clinical trials
  • Track 10-5Human vaccines
  • Track 10-6HIV/AIDS vaccines
  • Track 10-7HPV vaccines
  • Track 10-8Therapeutic vaccination for auto immune diseases
  • Track 10-9New vaccines
  • Track 10-10Veterinary vaccines
In this session we will focus on medical devices designed for drug delivery through the pulmonary and nasal routes. These routes are of interest for local delivery, as in asthma, but also for rapid delivery of drugs to the system circulation and direct delivery to the central nervous system. Devices that account for specific anatomical and physiological features of the intranasal and pulmonary routes will be featured. Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a specific route of administration. Such devices are used as part of one or more medical treatments. Many in the industry have long felt overly burdened by what they consider to be an unnecessarily complex approval process. Critics claim it impedes innovation and delays the availability of better health care. In order to help innovators bring health care to the public Pharmaceutica 2016 hosts drug delivery conferences throughout the year which happened to be the event pharma conference dubai in 2015.
 
To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other non-profit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.
 
The drug-device combination market is not fragmented and the key players in this market are Medtronic, Boston Scientific Corp., Edwards Life sciences Corp., Stryker Corp., QLT Inc. etc. The maximum number of new product developments is expected to take place in the bone graft substitutes, advanced wound care products and antimicrobial catheter markets. Our patent analysis indicates that E.U. has filed for the maximum number of patents followed by the U.S.
 
  • Track 11-1Biomedical Instrumentation Measurements
  • Track 11-2Measurement of Blood Flow and Cardiac Output
  • Track 11-3Instrumentation for Psychophysiological Measurements
  • Track 11-4Instrumentation for the Experimental Analysis of Behaviour
  • Track 11-5Respiratory Therapy Equipment
  • Track 11-6Pacemakers and Defibrillators
  • Track 11-7Quality by Design (QbD)
  • Track 11-8Instrumentation for the Medical Use of Radioisotopes
  • Track 11-9Ophthalmic and ENT Instruments
  • Track 11-10Ultrasonography
  • Track 11-11Computed Tomographic Scanning (CT Scanning)
  • Track 11-12Positron-Emission Tomographic (PET) Scanning
  • Track 11-13Magnetic Resonance Imaging

Peptides and proteins have great potential as therapeutics. Peptides can be designed to target a broad range of molecules, giving them almost limitless possibilities in fields such as oncology, immunology, infectious disease and endocrinology. While the peptide and protein therapeutic market has developed significantly in the past decades, delivery has limited their use. Although oral delivery is preferred, most are currently delivered intravenously or subcutaneously due to degradation and limited absorption in the gastrointestinal tract. Therefore, absorption enhancers, enzyme inhibitors, carrier systems and stability enhancers are being studied to facilitate oral peptide delivery. Additionally, transdermal peptide delivery avoids the issues of the gastrointestinal tract, but also faces absorption limitations. Due to proteases, opsonization and agglutination, free peptides are not systemically stable without modifications.

Currently, the market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market. This market is growing much faster than that of small molecules, and will make up an even larger proportion of the market in the future. At present there are over 100 approved peptide-based therapeutics on the market, with the majority being smaller than 20 amino acids. Compared with the typical small-molecule drugs that currently make up the majority of the pharmaceutical market, peptides and proteins can be highly selective as they have multiple points of contact with their target. Increased selectivity may also result in decreased side effects and toxicity.

 

  • Track 12-1Peptide Vector for Biologics Brain Delivery
  • Track 12-2Protein Formulation & Aggregation
  • Track 12-3Protein therapeutics
  • Track 12-4Polymers for delivery of proteins
  • Track 12-5Peptide therapeutics
  • Track 12-6Cell-penetrating and cell-targeting
The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S. constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% for 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists.
 
Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, quality control, and business development Business opportunities in drug delivery.

A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start and/or expand their business. Thus it is a perfect place to connect Entrepreneurs, Business Owners, Early Stage Companies and Established Corporates with National or International Investors, Corporate Investors and Potential Business Partners.